

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_81059
Title of the Manuscript:	ROLE OF TOCILIZUMAB IN FIGHTING COVID 19
Type of the Article	Review Article

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

**Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<p>I have reviewed the manuscript ROLE OF TOCILIZUMAB IN FIGHTING COVID 19 and it was interesting. However, in my opinion, the manuscript has deficiencies and must be reconsidered.</p> <p>I advise the authors to thoroughly revise the article in the following aspects:</p> <ol style="list-style-type: none"> <li>1. The manuscript needs to revise the stylistic and grammatic. I suggest the authors have the manuscript for proofreading for English.</li> <li>2. The authors need to include the objective of the review and add materials and methods. What databases were searched, what dates were set, in what period of time the authors searched, what keywords, etc?</li> <li>3. Abbreviations are defined after the first time used in the manuscript text. IL-6, CRP, TCZ, CFR.</li> <li>4. When discussing the clinical features of the COVID-19 disease, references should be provided.</li> <li>5. When mentioning clinical studies or individual reports, the authors must provide references.</li> <li>6. Authors should exclude duplicate sections and definitions.</li> <li>7. I recommend the authors discuss more than two studies on the use of tocilizumab in patients with COVID-19.</li> <li>8. Conclusions must be consistent with the main text of the manuscript. If the authors write in the conclusions about the treatment strategy for COVID-19 (bottom-up approach), then this fact must first be discussed in the main text.</li> </ol> <p>You will see an example of a reconsider below.</p> <ol style="list-style-type: none"> <li>1. The abstract must be optimized. If under the word "summary" the authors meant "results", then they should not repeat the background there. For example, the authors write in the background: "Tocilizumab is the repurposed drug used in the severely ill COVID-19 patients." And a few lines later: "Many drugs such as Hydroxychloroquine (HCQ), Tocilizumab were repurposed from their existing use." And so on through the text of the abstract.</li> </ol> <p>By the way, Hydroxychloroquine is not the same as Hydroxychloroquine.</p> <ol style="list-style-type: none"> <li>2. The authors need to provide references in the introduction to such sentences: "Many candidates are in line to get approved from drug controller agencies of various nations." "Another option of repurposing the existing drug among which Tocilizumab was one of the popular drugs." "It gained traction when several studies carried out in different parts of the world conveyed the positive response about the administration of drugs in severely ill patients."</li> </ol>	

Review Form 1.6

	<p>"Of course the drug is not made solely for the treatment of COVID-19 and has its limitations."</p> <p>3. Section "REPURPOSING EXISTING DRUGS"</p> <p>a) a viral disease cannot mutate. only SARS-CoV-2 can mutate.</p> <p>b) in what period of time was there no COVID-19 treatment protocol?</p> <p>c) if coronavirus genome sequencing opens up new opportunities for drug repurposing, please provide a reference to this study.</p> <p>4. Section "TOCILIZUMAB"</p> <p>a) if rheumatoid arthritis is a predominantly elderly disease, provide a reference. But is it? Are people 40 years old really elders? In addition, using the word old is incorrect.</p> <p>b) the abbreviation is indicated after the first mention in the text. for example, Interleukin-6 (IL-6).</p> <p>c) these two phrases will need to harmonize: "Rheumatoid arthritis is the commonly occurring condition among old age patients and it shows swollen and painful joints which becomes stiff post resting duration. It is used against the INterleukinn-6 receptor as the monoclonal antibody derived from non-human source and which is humanized in the due course of production."</p> <p>d) use conventional terms in this sentence "Tocilizumab is found to be lowering the IL-6 which is necessary in many cases as the body overkill the healthy cell along with the bad cells which can escalate in to organ failure."</p> <p>5. Section "TOCILIZUMAB IN COVID-19"</p> <p>a) Information in sections "TOCILIZUMAB" and "TOCILIZUMAB IN COVID-19" is duplicated. Please change this and add references.</p> <p>b) References are required here and other sections if authors mention clinical studies or single study reports. For example, in this sentence: "In one instance of study on the COVID-19 patients affected by ARDS and subsequently to pneumonia in Italy, Tocilizumab has shown promising results."</p> <p>c) the authors focused on only two studies on the use of tocilizumab in patients with COVID-19. Why these particular studies? Why are they remarkable?</p> <p>6. Section "LIMITATIONS OF USING TOCILIZUMAB"</p> <p>What specific parameters do the authors have in mind here? "IL-6, CRP and D-dimer are some of the parameters that are being used to administer the repurposed drugs." Please provide a reference.</p> <p>7. Section "PREVENTIVE MEASURES FOR COVID-19".</p> <p>Please remove the duplication in this section and add references. I recommend the authors in this section use generally accepted terms regarding post-COVID conditions too.</p>	
--	--	--

**Review Form 1.6**

<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments		

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>Olena Yelizarova</b>
Department, University & Country	<b>State Institution O.M. Marzieiev Institute For Public Health Of The National Academy Of Medical Sciences Of Ukraine, Ukraine</b>